Original Source(s)
Related Content
FDA approves combo for ESR1-mutated breast cancer
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
-
2 min
Newborn variants may flag childhood cancer predisposition
Targeted sequencing identified cancer-risk variants in about 7% of pediatric patients who later developed early-onset solid or brain malignancies.
August 28, 2026
-
4 min
AI cuts lesion measurement time by 34%
Automated lesion measurements increased agreement on treatment response, although expert-generated proposals were accepted more often and required fewer adjustments.
September 3, 2026
-
4 min
